Original document(76 pages)  中文版
    Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
Application Number
申请号		 200610090082 Application Date
申请日		 1993.11.12
Title 名称 Engomphosis and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen
Publication Number
公开号		 1912111 Publication Date
公开日		 2007.02.14
Approval Pub. Date Granted Pub. Date
International Classification 分类号 C12N5/10;C12N15/13;C12N15/85;C07K16/28;A61K39/395;A61K51/10;A61P35/00;A61K101/02;A61K103/32
Applicant(s) Name
申请人		 Biogen Idec Inc.
Address 地址
Inventor(s) Name 发明人 Anderson Darrell R.;Rastetter William H.;Hanna Nabil;Leonard John E.;Newman Roland A.;Reff Mitchell E.
Attorney & Agent 代理人 wu xiaonan bian xinqin
More information 更  多  信  息


 Related patents information
Google
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.